NYZ Stock Overview
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Novacyt S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.79 |
52 Week High | €0.94 |
52 Week Low | €0.39 |
Beta | -1.71 |
1 Month Change | 54.45% |
3 Month Change | 43.64% |
1 Year Change | 37.87% |
3 Year Change | -85.33% |
5 Year Change | 375.90% |
Change since IPO | 50.48% |
Recent News & Updates
Recent updates
Shareholder Returns
NYZ | DE Biotechs | DE Market | |
---|---|---|---|
7D | 6.9% | -1.2% | 1.7% |
1Y | 37.9% | -23.0% | 2.3% |
Return vs Industry: NYZ exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: NYZ exceeded the German Market which returned 2.3% over the past year.
Price Volatility
NYZ volatility | |
---|---|
NYZ Average Weekly Movement | 10.8% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NYZ's share price has been volatile over the past 3 months.
Volatility Over Time: NYZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 120 | James McCarthy | www.novacyt.com |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt S.A. Fundamentals Summary
NYZ fundamental statistics | |
---|---|
Market cap | €56.15m |
Earnings (TTM) | -€29.51m |
Revenue (TTM) | €9.18m |
6.1x
P/S Ratio-1.9x
P/E RatioIs NYZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NYZ income statement (TTM) | |
---|---|
Revenue | UK£7.87m |
Cost of Revenue | UK£4.84m |
Gross Profit | UK£3.03m |
Other Expenses | UK£28.33m |
Earnings | -UK£25.30m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.36 |
Gross Margin | 38.51% |
Net Profit Margin | -321.40% |
Debt/Equity Ratio | 0% |
How did NYZ perform over the long term?
See historical performance and comparison